BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21436673)

  • 1. Clinical versus pathologic staging for prostate adenocarcinoma: how do they correlate?
    Cooke EW; Shrieve DC; Tward JD
    Am J Clin Oncol; 2012 Aug; 35(4):364-8. PubMed ID: 21436673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting pelvic lymph node involvement in current-era prostate cancer.
    Rahman S; Cosmatos H; Dave G; Williams S; Tome M
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):906-10. PubMed ID: 21300478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era.
    Nguyen PL; Chen MH; Hoffman KE; Katz MS; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):104-9. PubMed ID: 19286330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
    Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
    J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
    Elliott SP; Johnson DP; Jarosek SL; Konety BR; Adejoro OO; Virnig BA
    J Urol; 2012 Jun; 187(6):2026-31. PubMed ID: 22498210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer.
    Yuh BE; Ruel NH; Mejia R; Wilson CM; Wilson TG
    Eur Urol; 2012 May; 61(5):1004-10. PubMed ID: 22366188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new formula for prostate cancer lymph node risk.
    Yu JB; Makarov DV; Gross C
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):69-75. PubMed ID: 20594769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series.
    Abdollah F; Cozzarini C; Suardi N; Gallina A; Capitanio U; Bianchi M; Tutolo M; Salonia A; La Macchia M; Di Muzio N; Rigatti P; Montorsi F; Briganti A
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):624-9. PubMed ID: 22099031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era.
    Dorin RP; Daneshmand S; Lassoff MA; Cai J; Skinner DG; Lieskovsky G
    Urology; 2012 Mar; 79(3):626-31. PubMed ID: 22245303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular invasion predicts recurrence after radical prostatectomy: stratification of risk based on pathologic variables.
    Ferrari MK; McNeal JE; Malhotra SM; Brooks JD
    Urology; 2004 Oct; 64(4):749-53. PubMed ID: 15491714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
    Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
    Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.
    Yamamoto S; Kawakami S; Yonese J; Fujii Y; Urakami S; Masuda H; Numao N; Ishikawa Y; Kohno A; Fukui I
    Jpn J Clin Oncol; 2012 Jun; 42(6):541-7. PubMed ID: 22457326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.